Artelo Biosciences Presents Preclinical Data on ART26.12 in Breast Cancer-Induced Bone Pain at the 34th Annual International Cannabinoid Research Society Symposium

Core Insights - Artelo Biosciences, Inc. is advancing its clinical-stage pharmaceutical development focused on lipid-signaling pathways to treat cancer, pain, and other conditions [1][6] - The company presented preclinical data on ART26.12, a novel fatty acid binding protein 5 (FABP5) inhibitor, at the 34th Annual International Cannabinoid Research Society Symposium [1][2] Group 1: Product Development - ART26.12 has shown efficacy in reducing pain behaviors associated with breast cancer in preclinical studies, consistent with previous findings in other pain models [2][3] - The drug is being developed as a non-opioid, non-steroidal analgesic treatment, with plans to initiate human trials pending FDA approval [3][4] - ART26.12 targets FABP5, which is overexpressed in various pathologies, and aims to address significant unmet needs in pain management [4][6] Group 2: Market Context - Breast cancer is the most common cancer in women, with over half of advanced cases leading to bone metastasis and associated pain [3] - The International Cannabinoid Research Society (ICRS) serves as a platform for researchers in the cannabinoid field, highlighting the growing interest in cannabinoid-related therapies [5]